USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ROCKLAND, INC.
Address:
650 ENGLESVILLE RD
BOYERTOWN, PA 19512-8407
Phone:
N/A
URL:
N/A
EIN:
131986244
DUNS:
58999129
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $149,866.00 1
SBIR Phase II $999,002.00 1

Award List:

TAS::75 0849::TAS SBIR TOPIC 292 PHASE I DEVELOPMENT OF MOLECULAR PHARMACODYNAMIC ASSAYS FOR TARGETED THERAPIES

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$149,866.00
Agency:
HHS
Principal Investigator:
David Chimento – 800-656-7625
Abstract:
The RON and c-MET signal pathways are critical regulators of cell growth, survival, migration, differentiation, and drug resistance. High levels of activated RON or c-MET have been observed in a number of human cancers. Activation of RON and c-MET by phosphorylation initiates a signal transduction… More

SBIR TOPIC 229, PHASE II: PHARMACODYNAMIC ASSAY FOR AKT FOR USE WITH PI3K/AKT/MTOR INHIBITORS

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$999,002.00
Agency:
HHS
Principal Investigator:
David Chimento – 800-656-7625
Abstract:
In response to this NCI solicitation, Rockland proposes to develop a novel method to assay the pharmacodynamic (PO) properties of anti-cancer small molecules targeting the PI3K/mTOR/AKT signaling pathway by quantitatively and independently measuring the phosphorylation of each unique AKT isoform in… More